Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions Adds: EasyJet
June 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1930 GMT on Monday:
** EasyJet EZJ.L and its investors are holding out for at least £600 million ($794.46 million) more from U.S. suitor Castlelake, the Financial Times reported on Monday, citing leading shareholders and people with knowledge of the talks.
[nL4N42U1FJ]
** Ireland's CRH <CRH.N> said it would acquire U.S.-based Arcosa <ACA.N> in an all-cash deal valued at about $8.5 billion, strengthening the building materials group's position in North America.
nL4N42U0RZ
** AbbVie <ABBV.N> will acquire biotech Apogee Therapeutics <APGE.O> for $10.9 billion in cash, they said, as the company builds its next-generation immunology pipeline.
nL4N42U0MZ
** Castlelake made public its £4.74 billion ($6.26 billion) takeover plan for easyJet <EZJ.L>, ramping up pressure on the board of the budget airline, which promptly rejected it as "opportunistic" and not in the best interests of shareholders.
nL1N42U08H
** French food giant Danone <DANO.PA> said it will acquire Australia's Made Group, expanding into high-protein foods in the Asia-Pacific region in a global race to tap surging demand from users of weight-loss drugs.
nL6N42U08M
(Compiled by Rajarshi Roy, Kunal Das and Pragyan Kalita in Bengaluru)
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)